Strattera, also known as atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It was first approved by the FDA in 2002 and has been a significant player in the ADHD treatment space since. Its non-stimulant nature and relatively low cost make it a popular choice among professionals.
The global ADHD market has been robust and is expected to grow at a compound annual growth rate (CAGR) of 5.7% to 6.4% from a 2012 inception to a size within a few years of approval expected to reach a CAGR of 7.0% to 8.5% during the forecast period (at theeding of 2023).
The global ADHD market is expected to grow at a CAGR of 7.0% to 8.5% from 2022 to 2029, with a growing market in key markets in the following regions:
Asthma, COPD, ADHD are some of the key factors contributing to the growth of the ADHD treatment market. The rising incidence of asthma, chronic obstructive pulmonary disease (COPD), and chronic bronchitis is significant growth projections for the ADHD treatment market.
CVS, Targeted Pharma, and Pfizer are some of the major players in the ADHD treatment market. In the year-earlier by year-except 2022, the ADHD market is driven by the increasing prevalence of ADHD by individuals in these regions.
Despite the positive growth prospects for the ADHD treatment market, the market faces some key restraints on its growth. These include:
The global ADHD treatment market is poised to experience the highest growth trajectory in 20 years. As the leading ADHD treatment market player, the demand for non-stimulants has increased, driven by the rising incidence of ADHD, as well as the availability of ADHD medication for a more comprehensive treatment approach.
The ADHD treatment market is driven by the increasing prevalence of ADHD, along with the rise of awareness and the practice of non-medication solutions. This demographic shift is leading to a shift away from solely using ADHD medication as a primary treatment option.
The Asia-Pacific region is expected to keep its market growth, with its non-stimulant ADHD treatment market expected to grow at a CAGR of 1.3% to 1.5% during the forecast period. This growth is likely due to the increasing incidence of ADHD, coupled with the growing demand for ADHD medication during this region’s lockdown period.
Europe is expected to grow at a CAGR of 1.
Atomoxetine, commonly known by its trade name Strattera, is a medication primarily used to treat attention deficit hyperactivity disorder (ADHD). It works by increasing the levels of certain chemicals in the brain. This increase in chemicals may help improve daily functioning, such as helping to control attention and reduce hyperactivity. Atomoxetine is available in several strengths, including 5 milligrams (mg), 10 mg, and 20 mg. This article will explore the benefits and potential side effects of Atomoxetine, including its intended use as a treatment for ADHD.
Atomoxetine is a medication primarily used to treat attention deficit hyperactivity disorder (ADHD).
Dosage varies depending on the patient's condition. It is crucial to follow the instructions provided by your healthcare provider when taking Atomoxetine, particularly if you have an underlying medical condition or are taking other medications. It is also essential to complete the full course of treatment to ensure the medication is effective. Regular monitoring of your body's response to the medication is recommended to ensure the effectiveness of the treatment.
Atomoxetine is primarily used to treat attention deficit hyperactivity disorder (ADHD).
Always follow your healthcare provider's instructions for the correct dosage and administration of Atomoxetine. This includes not taking more than the prescribed dosage, and not exceeding the recommended amount. It is important to complete the full course of treatment to ensure the medication is effective.
While Atomoxetine is generally well-tolerated, there are potential side effects and risks associated with its use. These include:
These side effects are usually mild and temporary. However, if you experience any unusual symptoms, such as mood changes, weakness, or confusion, it is important to notify your healthcare provider immediately.
Atomoxetine works by increasing the levels of certain chemicals in the brain. This increase in chemicals may help improve attention and reduce hyperactivity.
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI). By blocking the reuptake of norepinephrine, it helps improve attention and reduce hyperactivity. This may help reduce the risk of side effects such as nausea or dry mouth.
The recommended dosage for Atomoxetine is typically 10 mg, taken as needed about one hour before engaging in a daily activity routine. The maximum daily dose should not exceed 60 mg. It is important to follow your healthcare provider's instructions for the correct dosing schedule and duration.
Atomoxetine is available in various strengths, including 5 mg, 10 mg, and 20 mg. If you are prescribed Atomoxetine, your healthcare provider will provide a personalized dosage and schedule based on your individual needs and response.
Strattera, or atomoxetine, is a medication primarily prescribed for Attention Deficit Hyperactivity Disorder (ADHD). The drug's primary function is to stabilize the neurotransmitter imbalances associated with ADHD, thereby facilitating better attention and behavior control. Atomoxetine's ability to augment the effects of dopamine and norepinephrine in the brain, thus, helps improve overall attention span, impulsivity, and overall focus. In addition, it can help manage behavior problems that can have a negative impact on relationships and self-esteem.
Strattera works by selectively inhibiting the action of norepinephrine, a neurotransmitter responsible for regulating attention and impulse control. This action prevents the reuptake of norepinephrine by the presynaptic norepinephrine transporter. Consequently, atomoxetine inhibits the reuptake of norepinephrine, thereby enhancing its excitatory effects and slowing down the reuptake of norepinephrine. Its pharmacokinetic profile is similar to that of norepinephrine, and its bioavailability is comparable to that of norepinephrine.
Strattera is prescribed for ADHD and in adults. It is also prescribed in children with attention-deficit hyperactivity disorder (ADHD). It may be used in combination with other medications for ADHD, such as stimulant medications or cognitive-behavioral therapy (CBT). It can also be prescribed off-label for ADHD by a healthcare provider, but it should be taken into account the potential benefits and drawbacks associated with atomoxetine.
It is important to note that atomoxetine is not for treating premature ejaculation, and it may not have a significant impact on the ejaculatory phase of the sexual act. Patients should consult their doctor before using atomoxetine.
Strattera is available in various dosage forms, including oral tablets, as well as extended-release tablets and oral suspension. It is important to follow the prescribed dosage and duration of treatment as directed by your doctor. The maximum recommended dose is one tablet per day.
The dosage of atomoxetine may be adjusted based on the severity of the condition, the patient's response to treatment, and other medications. It is important to complete the full course of treatment as prescribed by your doctor. Strattera can be taken with or without food. However, if you are taking it with a high-fat meal, it may delay its absorption.
Strattera is generally well-tolerated, but it may cause side effects. Some of these include dry mouth, headache, and nausea. If these occur, they are generally mild and do not interfere with daily life or lifestyle. In some cases, they may subside with the cessation of the medication or with prolonged use.
Patients should be advised to consult their doctor if they experience any adverse reactions to atomoxetine. These may include nausea, vomiting, increased appetite, or difficulty sleeping. Regular monitoring of the patient's condition, medication intake, and any side effects should accompany the medication. If the patient is taking the medication with a high-fat meal, it may affect their metabolism, so it is important to avoid taking this type of medication in conjunction with it.
It is important to remember that Strattera can have serious interactions with other medications. For example, some medications may reduce the effectiveness of Strattera, while others may decrease the efficacy of other medications. It is important to discuss any concerns or potential interactions with your doctor before starting atomoxetine therapy.
In addition to the above precautions, it is important to note that atomoxetine is not a stimulant medication. Strattera should be used with caution if you have any of the following conditions:
It is also important to remember that Strattera can have an impact on the patient's quality of life.
Strattera is a medication that has been approved by the U. S. Food and Drug Administration (FDA) for the treatment of ADHD. It is also approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. However, Strattera doesn't provide an alternative to ADHD medications, and it should be used with caution.
The drug is also approved for the treatment of generalized anxiety disorder (GAD) and panic disorder. However, it has been shown in clinical studies to be effective in children, as well as adults with ADHD.
The drug is available as an oral tablet that comes in 5mg, 10mg, and 20mg tablets.
There are some side effects that may be experienced while taking Strattera, such as dizziness, nausea, and drowsiness. If you have taken Strattera, you should seek medical advice.
Strattera may not be suitable for children. The FDA does not approve the use of Strattera in children. However, the drug is not recommended for use in pregnant women or in women 65 years of age or older.
Strattera may interact with certain medications, including those that are known to the pharmacist as PDE5 inhibitors. These medications are considered to be non-nicotinic, non-selective, and non-specific.
The effects of Strattera may be affected by food, exercise, and alcohol. If you have been taking Strattera for the past 12 months or more, talk to your healthcare provider about the potential risks and benefits of taking the drug. Some people may have a higher risk of adverse effects from taking the drug, especially if they also have an underlying condition that makes Strattera less effective or if they take other medications that could potentially interact with Strattera.
This article is for informational purposes only and does not constitute medical advice. It should not be relied upon. Before taking this medication, you should talk to your healthcare provider about the risks and benefits of taking it.
Read More About StratteraStrattera may interact with certain medications, including those that are known as non-nicotinic, non-selective, and non-specific medications.
It should not be used for medical advice in treatment or for medical advice in patients. To obtain this article, call our toll-free number 1-877-468-9225 or visit us at
Stade de France Pharmacy